 Sorrento Therapeutics Inc. SRNE, -1.57 said Monday that initial laboratory testing of its Covistix COVID-19 virus rapid antigen detection test significantly outperforms in the detection of the omicron variant. The stock slipped 1.1 in morning trading. 